Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 136 to 150 of 315 results for breast cancer

  1. Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]

    In development Reference number: GID-TA11535 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Ocrelizumab for treating relapsing–remitting multiple sclerosis (TA533)

    Evidence-based recommendations on ocrelizumab (Ocrevus) for treating relapsing–remitting multiple sclerosis in adults.

    Technology appraisal guidance
    Published
    25 July 2018
    View recommendations

    Sections for TA533

  3. Lapatinib for breast cancer (first line use in advanced or metastatic hormone-sensitive breast cancer) [ID115]

    Discontinued Reference number: GID-TAG404

    Technology appraisal guidance
    Discontinued

  4. Board, executive team and senior leaders interests register

    Outside interests of the NICE board

  5. Artificial intelligence (AI) technologies to aid contouring for radiotherapy treatment planning: early value assessment (HTG695)

    Early value assessment (EVA) guidance on artificial intelligence (AI) technologies to aid contouring for radiotherapy treatment planning in people having external beam radiotherapy.

    HealthTech guidance
    Published
    27 September 2023
    View recommendations

    Sections for HTG695

  6. Sarcoma (QS78)

    This quality standard covers providing and organising services for people with sarcoma. It includes pathways for referral and diagnosis, treatment and support for adults, young people and children with sarcoma. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    29 January 2015
    View quality statements

    Sections for QS78

  7. Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401

    In development Reference number: GID-TA10326 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. NICE: backing the healthtech that changes lives

    Following the government’s 10 Year Health Plan for England, we're strengthening our role in getting the best healthtech, including digital tools, diagnostics and medical devices, to patients.

  9. Impact of risk-reducing surgery:- Further research is recommended to compare psychosocial and clinical outcomes in women who choose and women who do not choose to have risk-reducing surgery. [new 2013]

    Studies show that risk-reducing surgery significantly reduces risk of breast cancer, but there is insufficient evidence to decide...

    Research recommendation
    Published
    9 June 2015

  10. Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]

    Discontinued Reference number: GID-TAG403

    Technology appraisal guidance
    Discontinued

  11. Thyroid cancer: assessment and management (NG230)

    This guideline covers diagnosis and management of thyroid cancer in people aged 16 and over. It aims to reduce variation in practice and increase the quality of care and survival for people with thyroid cancer.

    NICE guideline
    Published
    19 December 2022
    View recommendations

    Sections for NG230

  12. Carrier probability calculation models:- Further research is recommended into developing and validating models for calculating carrier probability, which incorporate additional data, such as the molecular pathology of tumours and the prevalence of mutations in different ethnic groups. [new 2013]

    of mutations and need adjustment for pathological subtypes of breast and ovarian cancer, which are particularly associated...

    Research recommendation
    Published
    9 June 2015

  13. Neoadjuvant endocrine therapy in postmenopausal women:- Is there a benefit for neoadjuvant endocrine therapy in postmenopausal women with early breast cancer?

    for neoadjuvant endocrine therapy in postmenopausal women with early breast cancer? Any explanatory notes(if applicable) To find out why...

    Research recommendation
    Published
    11 December 2018

  14. Etirinotecan pegol for treating breast cancer with brain metastases [ID881]

    Discontinued Reference number: GID-TA10066

    Technology appraisal guidance
    Discontinued

  15. Pembrolizumab with neoadjuvant chemotherapy and adjuvant endocrine therapy for treating ER-positive, HER2-negative early breast cancer [ID3993]

    Awaiting development Reference number: GID-TA10896 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development